Compare BioNano Genomics Inc (BNGO) vs Capri Holdings Ltd (CPRI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Capri Holdings Ltd — how do they compare? BioNano Genomics Inc trades at $1.15 (market cap $13.20M), while Capri Holdings Ltd trades at $16.76 (market cap $1.91B). The key difference: Capri Holdings Ltd is far larger — about 144.7× BioNano Genomics Inc's market cap. Which is the better fit depends on your goals.
| BNGO | CPRI | |
|---|---|---|
Market Cap | $13.20M | $1.91B |
Sector | Health | Consumer Staples |
52-Week High | $4.92 | $27.66 |
52-Week Low | $1.09 | $16.68 |
Enterprise Value | $15.81M | $3.20B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
CPRI trades at $17.46, down 3.22% on the day, with a bearish technical signal from moving averages and oscillators neutral. The company reported a net loss of $1.18 billion in 2025 despite a gross profit margin of 62.26%. Recent news highlights a post-Versace turnaround focus on Michael Kors and Jimmy Choo, with management projecting fiscal 2027 growth. Analyst consensus is a buy rating with a $23.33 price target, implying significant upside from current levels.
The investment case hinges on successful execution of the two-brand strategy and return to profitability. Key risks include sustained luxury demand weakness and high debt levels, while potential rewards include valuation upside if earnings guidance is met. The stock presents a high-risk, high-reward opportunity contingent on operational improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Capri Holdings Ltd
Michael Kors, Versace, and Jimmy Choo are the brands of Capri Holdings, a marketer, distributor, and retailer of upscale accessories and apparel. Kors, Capri's largest brand, offers handbags, footwear, and apparel through more than 800 company-owned stores, wholesale, and e-commerce. Versace (acquired in 2018) is known for its ready-to-wear luxury fashion, while Jimmy Choo (acquired in 2017) is best known for women's luxury footwear. John Idol has served as CEO since 2003.
Read more on CPRI →
